These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 11095439

  • 1. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
    Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P, Morange-Ramos I, Cogne M, Jaquet P.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M, Gebbie J, Kendall-Taylor P.
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [Abstract] [Full Text] [Related]

  • 9. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G.
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [Abstract] [Full Text] [Related]

  • 10. Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications.
    Caron P, Tabarin A, Cogne M, Chanson P, Jaquet P.
    Eur J Endocrinol; 2000 Jun; 142(6):565-71. PubMed ID: 10822218
    [Abstract] [Full Text] [Related]

  • 11. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ, Group for Lanreotide Autogel Long-Term Study on Acromegaly.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W.
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL, Boschetti M, Degli Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M, Italian Multicenter Autogel Study Group in Acromegaly.
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [Abstract] [Full Text] [Related]

  • 14. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.
    Attanasio R, Barausse M, Cozzi R.
    J Endocrinol Invest; 2001 Apr; 24(4):209-16. PubMed ID: 11383906
    [Abstract] [Full Text] [Related]

  • 15. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM.
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [Abstract] [Full Text] [Related]

  • 16. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 17. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
    Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F.
    Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
    [Abstract] [Full Text] [Related]

  • 18. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
    Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R.
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5258-65. PubMed ID: 14602759
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
    Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A.
    Pituitary; 1999 Nov; 1(2):115-20. PubMed ID: 11081189
    [Abstract] [Full Text] [Related]

  • 20. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
    Caron P.
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.